We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2011. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2011. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

We thank those who reviewed manuscripts submitted to the Cleveland Clinic Journal of Medicine in the year ending December 31, 2011. Reviewing papers for scientific journals is an arduous task and involves considerable time and effort. We are grateful to these reviewers for contributing their expertise this past year.

—Brian F. Mandell, MD, PhD, Editor in Chief

A 26-year-old Filipino woman presented for evaluation of sternal pain associated with a palpable mass that she had noticed 8 months earlier. She had no history of significant medical illness. She had recently immigrated to El Paso, TX, from the Philippines.

Q: Which is the most likely diagnosis?

• Plasmacytoma
• Chondrosarcoma
• Extrapulmonary tuberculosis
• Lymphoma
• Metastatic breast cancer

EXTRAPULMONARY TUBERCULOSIS

Extrapulmonary tuberculosis accounts for about 20% of all cases of tuberculosis.¹

Risk factors for tuberculosis include advanced age, immunosuppression (eg, as occurs in HIV infection), organ transplantation, and therapy with a tumor necrosis factor alpha inhibitor.^1–4 Risk factors unique to extrapulmonary tuberculosis infection include female sex and non-Hispanic black ethnicity.² Because of the high prevalence of tuberculosis in certain parts of the world, obtaining a travel or residence history is an essential part of the clinical evaluation.

Skeletal tuberculosis accounts for 11% to 27% of extrapulmonary cases and, by extrapolation, 2% to 5% of all cases of tuberculosis.^1–3 Although the spine is the site most commonly involved, any bone may be affected. When the chest wall is involved, the most common locations are the margin of the sternum and along rib shafts.⁵

Most patients present with pain and swelling. The presence of constitutional symptoms is variable, occurring in about one-third of patients.⁶ Classically, the lesion of tuberculous osteomyelitis is described as a “cold abscess,” as it is characterized by swelling and erythema with little or no warmth. Spontaneous drainage and sinus tract formation may occur.⁵

The differential diagnosis of tuberculous osteomyelitis includes pyogenic bacterial infection, atypical bacterial infection (nocardia, meliodosis, brucellosis), fungal infection (coccidioidomycosis, histoplasmosis, blastomycosis), and metastatic and primary bone malignancies. Diagnosis requires a high index of suspicion, biopsy for histopathologic examination, acid-fast staining, and mycobacterial culture.⁷

Patients generally respond well to 6 months of a standard four-drug regimen for tuberculosis. Surgery is indicated for abscess drainage, debridement of infected tissue, spine stabilization, and relief of spinal cord compression.⁵

Our patient had complete resolution of her sternal mass with drug therapy alone.

A 26-year-old Filipino woman presented for evaluation of sternal pain associated with a palpable mass that she had noticed 8 months earlier. She had no history of significant medical illness. She had recently immigrated to El Paso, TX, from the Philippines.

Q: Which is the most likely diagnosis?

• Plasmacytoma
• Chondrosarcoma
• Extrapulmonary tuberculosis
• Lymphoma
• Metastatic breast cancer

EXTRAPULMONARY TUBERCULOSIS

Extrapulmonary tuberculosis accounts for about 20% of all cases of tuberculosis.¹

Risk factors for tuberculosis include advanced age, immunosuppression (eg, as occurs in HIV infection), organ transplantation, and therapy with a tumor necrosis factor alpha inhibitor.^1–4 Risk factors unique to extrapulmonary tuberculosis infection include female sex and non-Hispanic black ethnicity.² Because of the high prevalence of tuberculosis in certain parts of the world, obtaining a travel or residence history is an essential part of the clinical evaluation.

Skeletal tuberculosis accounts for 11% to 27% of extrapulmonary cases and, by extrapolation, 2% to 5% of all cases of tuberculosis.^1–3 Although the spine is the site most commonly involved, any bone may be affected. When the chest wall is involved, the most common locations are the margin of the sternum and along rib shafts.⁵

Most patients present with pain and swelling. The presence of constitutional symptoms is variable, occurring in about one-third of patients.⁶ Classically, the lesion of tuberculous osteomyelitis is described as a “cold abscess,” as it is characterized by swelling and erythema with little or no warmth. Spontaneous drainage and sinus tract formation may occur.⁵

The differential diagnosis of tuberculous osteomyelitis includes pyogenic bacterial infection, atypical bacterial infection (nocardia, meliodosis, brucellosis), fungal infection (coccidioidomycosis, histoplasmosis, blastomycosis), and metastatic and primary bone malignancies. Diagnosis requires a high index of suspicion, biopsy for histopathologic examination, acid-fast staining, and mycobacterial culture.⁷

Patients generally respond well to 6 months of a standard four-drug regimen for tuberculosis. Surgery is indicated for abscess drainage, debridement of infected tissue, spine stabilization, and relief of spinal cord compression.⁵

Our patient had complete resolution of her sternal mass with drug therapy alone.

A 26-year-old Filipino woman presented for evaluation of sternal pain associated with a palpable mass that she had noticed 8 months earlier. She had no history of significant medical illness. She had recently immigrated to El Paso, TX, from the Philippines.

Q: Which is the most likely diagnosis?

• Plasmacytoma
• Chondrosarcoma
• Extrapulmonary tuberculosis
• Lymphoma
• Metastatic breast cancer

EXTRAPULMONARY TUBERCULOSIS

Extrapulmonary tuberculosis accounts for about 20% of all cases of tuberculosis.¹

Risk factors for tuberculosis include advanced age, immunosuppression (eg, as occurs in HIV infection), organ transplantation, and therapy with a tumor necrosis factor alpha inhibitor.^1–4 Risk factors unique to extrapulmonary tuberculosis infection include female sex and non-Hispanic black ethnicity.² Because of the high prevalence of tuberculosis in certain parts of the world, obtaining a travel or residence history is an essential part of the clinical evaluation.

Skeletal tuberculosis accounts for 11% to 27% of extrapulmonary cases and, by extrapolation, 2% to 5% of all cases of tuberculosis.^1–3 Although the spine is the site most commonly involved, any bone may be affected. When the chest wall is involved, the most common locations are the margin of the sternum and along rib shafts.⁵

Most patients present with pain and swelling. The presence of constitutional symptoms is variable, occurring in about one-third of patients.⁶ Classically, the lesion of tuberculous osteomyelitis is described as a “cold abscess,” as it is characterized by swelling and erythema with little or no warmth. Spontaneous drainage and sinus tract formation may occur.⁵

The differential diagnosis of tuberculous osteomyelitis includes pyogenic bacterial infection, atypical bacterial infection (nocardia, meliodosis, brucellosis), fungal infection (coccidioidomycosis, histoplasmosis, blastomycosis), and metastatic and primary bone malignancies. Diagnosis requires a high index of suspicion, biopsy for histopathologic examination, acid-fast staining, and mycobacterial culture.⁷

Patients generally respond well to 6 months of a standard four-drug regimen for tuberculosis. Surgery is indicated for abscess drainage, debridement of infected tissue, spine stabilization, and relief of spinal cord compression.⁵

Our patient had complete resolution of her sternal mass with drug therapy alone.

A 42-year-old man presented with acute renal failure with a serum creatinine of 6.07 mg/dL (baseline 2.0 mg/dL) 6 months after receiving a kidney transplant from a deceased donor. He was asymptomatic, had no previous symptoms of transplant rejection, and was compliant with his immunosuppressive regimen. The physical examination and the rest of the laboratory workup were normal.

Q: Which is the most likely diagnosis?

• A lymphocele
• A hematoma
• A urinoma
• A perirenal abscess
• A simple renal cyst

A: A lymphocele is the most likely diagnosis. A lymphocele— a collection of lymph without an epithelial lining—develops in as many as 20% of kidney transplant recipients.¹ Many causative factors have been proposed, including leakage of lymph from recipient lymphatic channels,² use of diuretics,² obesity,³ kidney biopsy,⁴ acute rejection,³ and the use of sirolimus⁵ (Rapamune) and high-dose corticosteroids.⁶ Some believe that lymphoceles may also arise from severed lymphatic vessels of the donor-kidney allograft.⁷

Ultrasonography can usually distinguish a lymphocele from other fluid collections on the basis of fluid appearance, shape, and position. In most cases, the lymphocele is adjacent to the lower pole and medial to the allograft, and appears anechoic on ultrasonography, with a thin, distinct wall. The typical features on analysis of aspirated fluid—ie, a creatinine level approximately the same as in the serum, a low protein value, and a high lymphocyte count compared with serum values—confirm the diagnosis of lymphocele.

A hematoma can occur in any location and have a heterogeneous appearance, as it contains both clotted (echogenic) and unclotted (anechoic) blood. They are usually seen within the first 1 to 2 weeks after surgery and may also develop after trauma or renal biopsy.

A urinoma is a collection of urine outside the bladder, resulting from a ureteral leak. They are predominantly anechoic, with an often indistinct wall. If there is a clinical suspicion, the diagnosis can be confirmed on aspiration by a high creatinine level in the fluid compared with the serum value.

A perirenal abscess commonly presents with pain, fever, and a complex fluid collection on ultrasonography, sometimes with an air fluid level. Aspiration of purulent fluid confirms the diagnosis.

A simple renal cyst appears within or protruding from the renal parenchyma as a spherical or eggshaped fluid-filled sac with an anechoic lumen and no measurable wall thickness.

SYMPTOMS AND MANAGEMENT

Lymphoceles are mostly inconsequential but can cause renal failure by compressing the ureter, renal vessels, or renal allograft. Other manifestations may include pain and swelling at the kidney allograft site, wound drainage, unilateral lower-extremity edema, deep vein thrombosis due to compression of iliac veins,⁸ urinary urgency or frequency due to extrinsic bladder compression, and urinary retention.⁹

If the lymphocele is clinically significant, percutaneous drainage guided by ultrasonography is recommended as the initial curative procedure.¹⁰ Sclerotherapy with different chemical agents is effective, but success depends on the size of the lymphocele cavity.¹¹

If these conservative therapies fail, lymphocele unroofing into the peritoneal cavity is needed. This is accomplished by laparoscopy^12,13 or open surgery. Although laparoscopic drainage is considered the procedure of choice, open surgery may be required for multiloculated lymphoceles and those adjacent to vital structures.^14,15

Kidneys are the most commonly transplanted solid organs. Every year, about 16,000 kidney transplantations are performed in the United States. It is common for the primary care physician to initially see these patients in cases of associated complications. Internists must be aware of the common causes of acute renal failure in this population, eg, acute rejection, drug toxicity, and obstruction. Lymphoceles are an important cause of renal failure due to obstruction. Early recognition and appropriate treatment of this complication can improve the outcome of the allograft.

A 42-year-old man presented with acute renal failure with a serum creatinine of 6.07 mg/dL (baseline 2.0 mg/dL) 6 months after receiving a kidney transplant from a deceased donor. He was asymptomatic, had no previous symptoms of transplant rejection, and was compliant with his immunosuppressive regimen. The physical examination and the rest of the laboratory workup were normal.

Q: Which is the most likely diagnosis?

• A lymphocele
• A hematoma
• A urinoma
• A perirenal abscess
• A simple renal cyst

A: A lymphocele is the most likely diagnosis. A lymphocele— a collection of lymph without an epithelial lining—develops in as many as 20% of kidney transplant recipients.¹ Many causative factors have been proposed, including leakage of lymph from recipient lymphatic channels,² use of diuretics,² obesity,³ kidney biopsy,⁴ acute rejection,³ and the use of sirolimus⁵ (Rapamune) and high-dose corticosteroids.⁶ Some believe that lymphoceles may also arise from severed lymphatic vessels of the donor-kidney allograft.⁷

Ultrasonography can usually distinguish a lymphocele from other fluid collections on the basis of fluid appearance, shape, and position. In most cases, the lymphocele is adjacent to the lower pole and medial to the allograft, and appears anechoic on ultrasonography, with a thin, distinct wall. The typical features on analysis of aspirated fluid—ie, a creatinine level approximately the same as in the serum, a low protein value, and a high lymphocyte count compared with serum values—confirm the diagnosis of lymphocele.

A hematoma can occur in any location and have a heterogeneous appearance, as it contains both clotted (echogenic) and unclotted (anechoic) blood. They are usually seen within the first 1 to 2 weeks after surgery and may also develop after trauma or renal biopsy.

A urinoma is a collection of urine outside the bladder, resulting from a ureteral leak. They are predominantly anechoic, with an often indistinct wall. If there is a clinical suspicion, the diagnosis can be confirmed on aspiration by a high creatinine level in the fluid compared with the serum value.

A perirenal abscess commonly presents with pain, fever, and a complex fluid collection on ultrasonography, sometimes with an air fluid level. Aspiration of purulent fluid confirms the diagnosis.

A simple renal cyst appears within or protruding from the renal parenchyma as a spherical or eggshaped fluid-filled sac with an anechoic lumen and no measurable wall thickness.

SYMPTOMS AND MANAGEMENT

Lymphoceles are mostly inconsequential but can cause renal failure by compressing the ureter, renal vessels, or renal allograft. Other manifestations may include pain and swelling at the kidney allograft site, wound drainage, unilateral lower-extremity edema, deep vein thrombosis due to compression of iliac veins,⁸ urinary urgency or frequency due to extrinsic bladder compression, and urinary retention.⁹

If the lymphocele is clinically significant, percutaneous drainage guided by ultrasonography is recommended as the initial curative procedure.¹⁰ Sclerotherapy with different chemical agents is effective, but success depends on the size of the lymphocele cavity.¹¹

If these conservative therapies fail, lymphocele unroofing into the peritoneal cavity is needed. This is accomplished by laparoscopy^12,13 or open surgery. Although laparoscopic drainage is considered the procedure of choice, open surgery may be required for multiloculated lymphoceles and those adjacent to vital structures.^14,15

Kidneys are the most commonly transplanted solid organs. Every year, about 16,000 kidney transplantations are performed in the United States. It is common for the primary care physician to initially see these patients in cases of associated complications. Internists must be aware of the common causes of acute renal failure in this population, eg, acute rejection, drug toxicity, and obstruction. Lymphoceles are an important cause of renal failure due to obstruction. Early recognition and appropriate treatment of this complication can improve the outcome of the allograft.

A 42-year-old man presented with acute renal failure with a serum creatinine of 6.07 mg/dL (baseline 2.0 mg/dL) 6 months after receiving a kidney transplant from a deceased donor. He was asymptomatic, had no previous symptoms of transplant rejection, and was compliant with his immunosuppressive regimen. The physical examination and the rest of the laboratory workup were normal.

Q: Which is the most likely diagnosis?

• A lymphocele
• A hematoma
• A urinoma
• A perirenal abscess
• A simple renal cyst

A: A lymphocele is the most likely diagnosis. A lymphocele— a collection of lymph without an epithelial lining—develops in as many as 20% of kidney transplant recipients.¹ Many causative factors have been proposed, including leakage of lymph from recipient lymphatic channels,² use of diuretics,² obesity,³ kidney biopsy,⁴ acute rejection,³ and the use of sirolimus⁵ (Rapamune) and high-dose corticosteroids.⁶ Some believe that lymphoceles may also arise from severed lymphatic vessels of the donor-kidney allograft.⁷

Ultrasonography can usually distinguish a lymphocele from other fluid collections on the basis of fluid appearance, shape, and position. In most cases, the lymphocele is adjacent to the lower pole and medial to the allograft, and appears anechoic on ultrasonography, with a thin, distinct wall. The typical features on analysis of aspirated fluid—ie, a creatinine level approximately the same as in the serum, a low protein value, and a high lymphocyte count compared with serum values—confirm the diagnosis of lymphocele.

A hematoma can occur in any location and have a heterogeneous appearance, as it contains both clotted (echogenic) and unclotted (anechoic) blood. They are usually seen within the first 1 to 2 weeks after surgery and may also develop after trauma or renal biopsy.

A urinoma is a collection of urine outside the bladder, resulting from a ureteral leak. They are predominantly anechoic, with an often indistinct wall. If there is a clinical suspicion, the diagnosis can be confirmed on aspiration by a high creatinine level in the fluid compared with the serum value.

A perirenal abscess commonly presents with pain, fever, and a complex fluid collection on ultrasonography, sometimes with an air fluid level. Aspiration of purulent fluid confirms the diagnosis.

A simple renal cyst appears within or protruding from the renal parenchyma as a spherical or eggshaped fluid-filled sac with an anechoic lumen and no measurable wall thickness.

SYMPTOMS AND MANAGEMENT

Lymphoceles are mostly inconsequential but can cause renal failure by compressing the ureter, renal vessels, or renal allograft. Other manifestations may include pain and swelling at the kidney allograft site, wound drainage, unilateral lower-extremity edema, deep vein thrombosis due to compression of iliac veins,⁸ urinary urgency or frequency due to extrinsic bladder compression, and urinary retention.⁹

If the lymphocele is clinically significant, percutaneous drainage guided by ultrasonography is recommended as the initial curative procedure.¹⁰ Sclerotherapy with different chemical agents is effective, but success depends on the size of the lymphocele cavity.¹¹

If these conservative therapies fail, lymphocele unroofing into the peritoneal cavity is needed. This is accomplished by laparoscopy^12,13 or open surgery. Although laparoscopic drainage is considered the procedure of choice, open surgery may be required for multiloculated lymphoceles and those adjacent to vital structures.^14,15

Kidneys are the most commonly transplanted solid organs. Every year, about 16,000 kidney transplantations are performed in the United States. It is common for the primary care physician to initially see these patients in cases of associated complications. Internists must be aware of the common causes of acute renal failure in this population, eg, acute rejection, drug toxicity, and obstruction. Lymphoceles are an important cause of renal failure due to obstruction. Early recognition and appropriate treatment of this complication can improve the outcome of the allograft.

To the Editor: In their excellent review of cervical cancer screening,¹Jin and colleagues discussed the current screening guidelines advocated by various medical organizations. The authors wisely advised clinicians to modify these guidelines when the lifestyle of an individual patient differs from the expected behavior of the patient’s peer group. For example, they said “it is probably reasonable to continue screening in women age 70 and older who are sexually active with multiple partners and who have a history of abnormal Pap test results.”

To this I would add that it seems reasonable to continue screening a woman over 70 who is sexually active with multiple partners, even if she still has no history of abnormal Pap test results. Similar reasoning might be applied to the statement, “women age 30 and older who had negative results on both Pap and HPV testing should be screened no more often than every 3 years.” This makes sense on a population-wide basis, since women over 30 are more likely to be married and have fewer sexual partners. But why should women who continue to have multiple sex partners into their 30s be screened any less frequently than women in their 20s?

The high negative predictive value of HPV-plus-Pap testing is based on the risk characteristics of the population being screened, as well as on the technical characteristics of the tests. Rigid adherence to screening guidelines may be a disservice to individuals whose lifestyles place them at higher risk than the norm for their age cohort.

To the Editor: In their excellent review of cervical cancer screening,¹Jin and colleagues discussed the current screening guidelines advocated by various medical organizations. The authors wisely advised clinicians to modify these guidelines when the lifestyle of an individual patient differs from the expected behavior of the patient’s peer group. For example, they said “it is probably reasonable to continue screening in women age 70 and older who are sexually active with multiple partners and who have a history of abnormal Pap test results.”

To this I would add that it seems reasonable to continue screening a woman over 70 who is sexually active with multiple partners, even if she still has no history of abnormal Pap test results. Similar reasoning might be applied to the statement, “women age 30 and older who had negative results on both Pap and HPV testing should be screened no more often than every 3 years.” This makes sense on a population-wide basis, since women over 30 are more likely to be married and have fewer sexual partners. But why should women who continue to have multiple sex partners into their 30s be screened any less frequently than women in their 20s?

The high negative predictive value of HPV-plus-Pap testing is based on the risk characteristics of the population being screened, as well as on the technical characteristics of the tests. Rigid adherence to screening guidelines may be a disservice to individuals whose lifestyles place them at higher risk than the norm for their age cohort.

To the Editor: In their excellent review of cervical cancer screening,¹Jin and colleagues discussed the current screening guidelines advocated by various medical organizations. The authors wisely advised clinicians to modify these guidelines when the lifestyle of an individual patient differs from the expected behavior of the patient’s peer group. For example, they said “it is probably reasonable to continue screening in women age 70 and older who are sexually active with multiple partners and who have a history of abnormal Pap test results.”

To this I would add that it seems reasonable to continue screening a woman over 70 who is sexually active with multiple partners, even if she still has no history of abnormal Pap test results. Similar reasoning might be applied to the statement, “women age 30 and older who had negative results on both Pap and HPV testing should be screened no more often than every 3 years.” This makes sense on a population-wide basis, since women over 30 are more likely to be married and have fewer sexual partners. But why should women who continue to have multiple sex partners into their 30s be screened any less frequently than women in their 20s?

The high negative predictive value of HPV-plus-Pap testing is based on the risk characteristics of the population being screened, as well as on the technical characteristics of the tests. Rigid adherence to screening guidelines may be a disservice to individuals whose lifestyles place them at higher risk than the norm for their age cohort.

The ability to scan the entire human genome and to recognize variations in specific nucleotides within recognized genes is more than a technologic feat. It is now possible to assess the risk of some genetic diseases before they are phenotypically expressed. We are increasingly able to predict whether specific drugs will be effective or pose higher risks of adverse effects in individual patients, a field called pharmacogenomics. How much pharmacogenomics can and should be incorporated into our practice as part of personalized medicine remains to be determined,

Genome-wide association studies can answer certain research questions, but also raise additional ones. In some ways, these studies are like molecular epidemiology—they can demonstrate a statistical association between a risk factor and a clinical event such as a heart attack, but just as in traditional epidemiologic studies, association does not always equate with causation.

As discussed by Drs. Manace and Babyatsky in this issue of the Journal, additional techniques can be used to try to sort out the issue of association vs causation—in this case, whether C-reactive protein (CRP) is merely associated with cardiovascular events or is a cause of them. Using the tools of traditional clinical research, it would be ideal to demonstrate that the use of a highly specific inhibitor of the risk factor (CRP) prevents the disease. CRP levels can be lowered with statins, but these drugs also reduce levels of low-density lipoprotein cholesterol, which will lower the risk of cardiac events. Thus, statins do not have the specificity to prove that CRP causes myocardial infarction.

This paper is one of the first in the Journal to discuss advances in genomics that may affect our practice. Beginning in May, the Journal will begin a new series on personalized medicine to highlight the role that genetics and molecular medicine can play in our clinical practice and in our understanding of pathophysiology.

The ability to scan the entire human genome and to recognize variations in specific nucleotides within recognized genes is more than a technologic feat. It is now possible to assess the risk of some genetic diseases before they are phenotypically expressed. We are increasingly able to predict whether specific drugs will be effective or pose higher risks of adverse effects in individual patients, a field called pharmacogenomics. How much pharmacogenomics can and should be incorporated into our practice as part of personalized medicine remains to be determined,

Genome-wide association studies can answer certain research questions, but also raise additional ones. In some ways, these studies are like molecular epidemiology—they can demonstrate a statistical association between a risk factor and a clinical event such as a heart attack, but just as in traditional epidemiologic studies, association does not always equate with causation.

As discussed by Drs. Manace and Babyatsky in this issue of the Journal, additional techniques can be used to try to sort out the issue of association vs causation—in this case, whether C-reactive protein (CRP) is merely associated with cardiovascular events or is a cause of them. Using the tools of traditional clinical research, it would be ideal to demonstrate that the use of a highly specific inhibitor of the risk factor (CRP) prevents the disease. CRP levels can be lowered with statins, but these drugs also reduce levels of low-density lipoprotein cholesterol, which will lower the risk of cardiac events. Thus, statins do not have the specificity to prove that CRP causes myocardial infarction.

This paper is one of the first in the Journal to discuss advances in genomics that may affect our practice. Beginning in May, the Journal will begin a new series on personalized medicine to highlight the role that genetics and molecular medicine can play in our clinical practice and in our understanding of pathophysiology.

The ability to scan the entire human genome and to recognize variations in specific nucleotides within recognized genes is more than a technologic feat. It is now possible to assess the risk of some genetic diseases before they are phenotypically expressed. We are increasingly able to predict whether specific drugs will be effective or pose higher risks of adverse effects in individual patients, a field called pharmacogenomics. How much pharmacogenomics can and should be incorporated into our practice as part of personalized medicine remains to be determined,

Genome-wide association studies can answer certain research questions, but also raise additional ones. In some ways, these studies are like molecular epidemiology—they can demonstrate a statistical association between a risk factor and a clinical event such as a heart attack, but just as in traditional epidemiologic studies, association does not always equate with causation.

As discussed by Drs. Manace and Babyatsky in this issue of the Journal, additional techniques can be used to try to sort out the issue of association vs causation—in this case, whether C-reactive protein (CRP) is merely associated with cardiovascular events or is a cause of them. Using the tools of traditional clinical research, it would be ideal to demonstrate that the use of a highly specific inhibitor of the risk factor (CRP) prevents the disease. CRP levels can be lowered with statins, but these drugs also reduce levels of low-density lipoprotein cholesterol, which will lower the risk of cardiac events. Thus, statins do not have the specificity to prove that CRP causes myocardial infarction.

This paper is one of the first in the Journal to discuss advances in genomics that may affect our practice. Beginning in May, the Journal will begin a new series on personalized medicine to highlight the role that genetics and molecular medicine can play in our clinical practice and in our understanding of pathophysiology.

Genomics research is paying off, not only by identifying people at risk of rare inherited diseases but also by clarifying the pathogenic mechanisms of important, common ones.

Thanks to advances in technology, we can now, at a reasonable cost, simultaneously screen for millions of genetic variants in thousands of people to find variants that are more common in people with a given disease than without the disease, a fruitful method called a genome-wide association study. Moreover, an epidemiologic method called mendelian randomization takes advantage of the natural reshuffling of the genetic deck that occurs with each generation to give an estimate of whether certain gene products are mediators—or merely markers—of disease.

In a landmark study published in 2009, Elliott et al¹ used mendelian randomization to evaluate the role of C-reactive protein (CRP) in coronary artery disease.

Here, we review the use of genetic tools in a clinical context, highlighting CRP to illustrate some of the potential uses and limitations of applied genomics in clinical investigation.

NATURE VS NURTURE: AN AGE-OLD DEBATE

The relative contributions of genetic and environmental factors to human health and disease— nature vs nurture—is an age-old debate in which interest has been renewed in this era of intensive research in molecular genetics.

In the 19th century, Charles Darwin proposed that evolution proceeds through natural selection of variations in inherited traits. His contemporary, Gregor Mendel, showed that traits are inherited in discrete units, later named genes. Just what genes were and how they worked had to await the discovery of the structure of DNA in 1953, by Watson and Crick.²

Since then, progress has accelerated. Advances in recombinant DNA and DNA-sequencing technologies enabled sequencing of the entire human genome only 50 years later. More recently, we have seen automated rapid sequencing, the HapMap project (more on this below), and the advent of genome-wide association studies that uncover genetic variants correlated with or predisposing to common, complex human diseases.

Until recent years, medical genetics was mostly confined to the study of rare syndromes, such as Huntington disease, that are due either to a change in a single gene or to abnormal quantities of large swaths of chromosomes containing many genes. It had little application to most of the common disorders seen by primary care physicians. However, the genes and pathways implicated in rare monogenic disorders have provided key insights into common diseases. For example, defining the genes and mutations underlying familial hypercholesterolemia highlighted the role of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerotic disease.

3.4 BILLION BASE PAIRS, 23,000 GENES

The DNA molecule consists of two strings of the nucleotides guanine (G), cytosine (C), thymine (T), and adenine (A). The human genome contains about 3.4 billion of these nucleotides, also called base pairs, as they bind G to C and A to T across the length of the double helix of the DNA molecule.

Only about 2% of these 3.4 billion base pairs make up genes, ie, sequences that are transcribed into RNA and then translated into protein. Humans have only about 23,000 genes, which is less than in some plant species.

What about the rest of the human genome, ie, most of it? Previously dismissed as “junk,” these regions likely possess more elusive regulatory functions, controlling gene expression (ultimately, the production of protein), which varies considerably from tissue to tissue and over a person’s lifetime.

It is the orchestration of gene expression over time and cell type that gives the human body its intricate complexity. The study of how all our genes and gene products interact is called genomics and is part of the larger topic of the network of protein interactions (proteomics) and of the integration of various protein pathways (metabolomics).

We are all 99% identical—or 12 million nucleotides different

Human genome sequences are 99% identical across populations. But the remaining 1% is still a big number: there are more than 12 million variants between any two individuals’ genomes. These variants include:

• Single-nucleotide polymorphisms (SNPs), ie, a single-nucleotide change that is present in at least 1% of the population
• Copy number variants (CNVs), ie, a stretch of DNA that is either missing or duplicated
• Repeating patterns of DNA that vary in the number of repeated sequences.

THE EVOLUTION OF GENOMICS RESEARCH

Much of the initial focus of research in the genomics era consisted of identifying these variants and discovering associations between them and particular human diseases or clinical outcomes. In this way, we uncovered a multitude of potential new biomarkers and therapeutic targets, requiring further investigation into the connection between the DNA variant and the clinical state.

At the close of the 20th century, genetic factors were correlated with human disease by linkage analysis (a method of mapping patterns of markers that congregate in relatively narrow regions of DNA in families with specific diseases), and candidate gene approaches, whereby genes were investigated on the basis of their postulated biology and of previous studies. These techniques were relatively low-yield and cumbersome; years of work uncovered only a handful of genes proven to be associated with diseases.

Newer tools can look at scores of genes linked to common diseases. Researchers now rely on sophisticated DNA sequencing tools and interpretation software to sift masses of data to find meaningful markers (DNA variants or mutations).

Genomics research in the past few years has been mostly hypothesis-independent. Investigators are no longer limited to the small cache of genes whose corresponding proteins are well characterized, but can instead probe the entire genome for connections between our DNA and our physiology.

Over the past decade, much clinically useful information has been gathered in genome-wide association studies.

The rise of this type of study rested on our emerging understanding of the architecture of our genome. When the genomes of multiple humans were fully sequenced, we discovered that specific variants do not occur randomly in relation to each other. Rather, they tend to be inherited in particular blocks called haplotypes, and some SNPs or combinations of SNPS are very rare or essentially never seen.

In its first phase, the HapMap project organized these useful blocks of variants, genotyping 1 million SNPs for each of 270 individuals from mother-father-offspring trios from distinct geographic regions of the world.³ The second phase of the HapMap project extended the analysis to more than 3 million SNPs and to other populations.⁴

While the HapMap should be generally applicable to other populations not yet studied, limitations of the first two HapMap phases include rare SNPs or CNVs, or variants outside of haplotype regions.

The 1,000 Genomes Project, now under way, will develop an even more comprehensive catalog of human genetic variants in much broader populations.

The success of genome-wide association studies is also partly attributable to progress in DNA-sequencing technology. Using microarray chips, we can now look at millions of SNPs per patient or the entire coding sequence of the genome (termed the exome) in a single experiment that is both time-effecient and cost-effective.

What is a genome-wide association study?

A genome-wide association study generally compares genetic variants between patients with a particular clinical condition (cases) and people without the condition (controls), looking for statistically significant differences. As a tool for genetic discovery, these studies have revealed many avenues for further investigation in the pathogenesis of disease, as well as potential targets of therapy.

Using these studies, research groups around the world have found reproducible correlations between genetic variants and susceptibility to common adult-onset diseases.

Although many of the variants identified in these studies are associated with only a slightly higher risk of disease, the method is free of many of the inherent biases associated with clinical research. These studies permit a comprehensive, hypothesis-independent and unbiased scan of the genome to identify novel susceptibility factors, whereas earlier genetic epidemiology studies could take on only a handful of variables to evaluate at a time. Additionally, they are powered to detect very small increases (or decreases) in disease risk, previously outside the reach of linkage analysis. Polymorphisms (or, presumably, non-disease-causing DNA changes) discovered using these studies often correlate with clinical phenotypes or with levels of biomarkers, even if the genetic variants are not necessarily pathologic in themselves.

Thus, genome-wide association studies have led to important insights into the pathogenesis of multiple common diseases, such as inflammatory bowel disease and diabetes mellitus, and they are facilitating new treatment approaches. For instance, multiple studies have reproduced an association between Crohn disease and variation in the gene NOD2, whose protein product is implicated in bacterial product recognition, autophagy, and apoptosis.⁵ This discovery led to the investigation of new potential therapies for Crohn disease, ie, the tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva), known to inhibit NOD2 activity, and to the prognostic use of the NOD2 genotype in Crohn disease (a field of study known as genotype-phenotype correlation).

Future advances will likely come from looking at combinations of variants, which may carry a higher risk of disease than single variants.

CORONARY HEART DISEASE: FRESH INSIGHT INTO AN OLD PROBLEM

Cardiovascular disease accounts for 30% of deaths worldwide.⁶ Of all the cardiovascular disorders, coronary heart disease is rising most rapidly in incidence, as the rest of the world adopts Western practices such as a high-calorie, high-fat, high-glycemic diet.

Hundreds of risk factors for coronary heart disease have been described.⁷ Three of them are clearly modifiable participants in the pathogenesis of atherosclerosis: hypertension, smoking, and elevated LDL-C. These and others form the basis for risk-assessment tools such as the Framingham risk score and the Prospective Cardiovascular Münster (PROCAM) study score. Other possible markers require further evaluation as to whether they are clinically useful and are direct mediators of coronary heart disease.

Because up to 40% of coronary deaths occur in people who lack conventional risk factors for it (eg, they do not smoke and they have normal levels of LDL-C and blood pressure), researchers are searching hard for new, potentially treatable risk factors.⁸ Of particular interest are components of inflammatory pathways linked with atherosclerosis and coronary heart disease. The identity of the key inflammatory factors that cause arterial plaque formation and rupture continues to be studied.

CRP, an acute-phase reactant produced by the liver in response to inflammation, has received much attention, as serum CRP levels correlate strongly with coronary events. Researchers have used modifiers of CRP to try to alter the course of coronary heart disease, but traditional research has so far failed to establish a causal relationship between CRP and coronary heart disease.⁹

How we know that LDL-C is a mediator, not just a marker

As a risk factor, LDL-C resembles CRP in that its levels correlate with a number of other, confounding risk factors. Therefore, much basic research and clinical observation had to be done before we could say that LDL-C plays a role in the pathogenesis of coronary heart disease.

Initially an association between LDL-C and heart disease was noted.¹⁰ Then, studies of familial hypercholesterolemia uncovered genetic abnormalities that increase LDL-C levels and, thereby, the risk of coronary heart disease—eg, mutations in the LDL receptor gene,^11–14 the apolipoprotein B (APOB) gene at its LDL receptor-binding domain,¹⁵LDL-RAP1 (a gene encoding an accessory adaptor protein that interacts with the LDL receptor),¹⁶ and PCSK9 (a gene that codes for proprotein convertase subtilisin-kexin type 9 protease).¹⁷

Conversely, specific loss-of-function truncating mutations of PCSK9 that reduce LDL-C levels are associated with strong protection against coronary heart disease.¹⁸ Other gene mutations that reduce LDL-C also lower the risk.^19,20

Further, a genome-wide association study²¹ identified multiple genetic variations associated with different forms of dyslipidemia, uncovering additional links between LDL-C and coronary heart disease.

Finally, randomized controlled trials of niacin, fibrates, and statins showed that these potent LDL-C-lowering agents reduce the rate of development or progression of coronary heart disease.^22,23

Unlike LDL-C, no familial syndromes of coronary heart disease have been recognized in patients who have isolated high serum levels of CRP.

Since many substances in addition to CRP increase in concentration in both acute and chronic inflammatory states, agents that lower CRP in a targeted manner would be needed for large prospective, randomized trials to show whether CRP plays a direct role in coronary heart disease. A specific CRP inhibitor, 1,6-bis(phosphocholine)-hexane, may aid in these efforts, although it is not orally bioavailable and has a very short serum half-life.²⁴

The JUPITER trial. Statins lower levels of both LDL-C and CRP. The Justification for the Use of Statins in Primary Prevention: an Intervention Evaluating Rosuvastatin (JUPITER) trial was designed to find out whether statins alter coronary risk in patients with “normal” LDL-C levels (< 130 mg/dL) and elevated CRP levels (> 2 g/L).²⁵

In this prospective, randomized trial, statin treatment resulted in a dramatic risk reduction of 40% to 50% in multiple coronary end points, as well as a reduction in CRP levels of 37% compared with placebo. However, LDL-C levels fell by 50%, confounding the effect on CRP, as the lower coronary event rate could alternatively be explained by the effect of lower-than-normal LDL-C levels. Thus, a causative link between CRP and coronary heart disease could not be proved.²⁶

Though ongoing trials may further illuminate the role of inflammation in the development of coronary heart disease, and specific CRP inhibitors are in development, we have few tools to answer the fundamental question of whether CRP itself is an active participant in cardiovascular disease progression or if it is a bystander marker, helping to define risk for patients who develop coronary heart disease without other known risk factors.

Of note, adding CRP to the Framingham risk score does not improve its predictive power very much in any age group.^27,28 Nevertheless, for certain end points, such as the long-term rate of death after percutaneous coronary intervention²⁹ or of cardiovascular death immediately after coronary artery bypass grafting,³⁰ CRP levels predict coronary events reliably.

BIOMARKERS AND MENDELIAN RANDOMIZATION

Further insight into the CRP-coronary association may lie in the genes. Intriguingly, while mutations have been found that alter the serum concentration of CRP, these isolated changes in CRP levels have not yet been shown to affect heart disease risk.^9,31,32

If one were to design a prospective, interventional study to evaluate the role of CRP in coronary heart disease, it would be very difficult to tease apart the specific impact of CRP from that of other variables that are often present in people with high CRP, such as obesity and hyperlipidemia. The technique of mendelian randomization offers a way to evaluate the correlation between coronary heart disease development and CRP levels independent of other risk factors.

How many heart attacks in people with or without polymorphisms?

Mendelian randomization takes advantage of a basic genetic principle, ie, the independent assortment of traits. According to Mendel’s second law, alleles for different traits are inherited independently of one another. Therefore, the gene that encodes CRP and other genes that influence its circulating level are presumably inherited independently from other genes that influence coronary risk.

In typical studies of CRP, participants are grouped according to whether they have high or low CRP levels. In these studies, confounding variables congregate in these two groups. For example, people with high CRP may be more likely to smoke and to have a higher body mass index and higher lipid levels—all of which influence cardiovascular outcomes. It is therefore difficult to tease out the effect of CRP levels from other background risk factors.

In contrast, in studies using mendelian randomization, patients are grouped according to whether they have a variant that affects the substance being studied (eg, CRP), and outcomes are compared between the two genetic groups.

Strengths and limitations of this method

By randomizing research subjects by gene variants affecting CRP levels, it is theoretically possible to achieve more equal stratification and minimize confounding between subgroups.³³

Mendelian randomization should also address the possibility of “reverse causality,” when the intermediate trait with a potential role in disease development (eg, CRP) is actually regulated by the disease state itself (ie, “inflammation of atherosclerotic cardiovascular disease”).³⁴

A limitation of mendelian randomization is that different genes influencing the biomarker under investigation must be proven to be truly randomly assorted among populations. It cannot be assumed that levels of a biomarker are equally distributed across cases and controls when there may in fact be non-random genetic associations.

For instance, if SNPs in various genes that affect creatine kinase levels were being compared to cardiovascular outcome, it would be important to take into account that baseline creatine kinase levels are higher in African Americans as well as in men in interpreting the study data.³⁵

THE ELLIOTT STUDY (2009)

In a study published in 2009, Elliott et al¹ mined genome-wide data collected over the last decade to bring more clarity to the issue of causality between elevated CRP and heart disease.

To accomplish mendelian randomization, the authors assessed SNPs that affect circulating CRP levels in combined sets of 28,000 cases and 100,000 controls—robust population sizes. The SNP variants included were associated with approximately 20% lower CRP levels. This degree of CRP reduction should correspond to a 6% reduction in coronary risk as predicted by meta-analysis of observational studies.

The authors found significant associations between these SNPs and CRP levels and between CRP levels and coronary heart disease, but not between the SNPs and coronary disease when results for three SNPs were combined and standardized to a 20% lower CRP level (odds ratio 1.00, 95% confidence interval 0.97–1.02).¹

In view of the lack of association between coronary heart disease and SNPs that affect CRP levels, the authors suggested that the observational data linking CRP levels and coronary disease may have been confounded by other risk factors, or that the trend is due to reverse causation (the inflammatory response associated with atherosclerosis elevates CRP) rather than CRP’s directly causing heart disease.

These findings have important implications for management of cardiovascular disease, as therapeutic strategies to reduce plasma CRP levels are less likely to be beneficial.

The authors also described other genetic variants that may affect coronary heart disease. Carriers of minor alleles of SNPs in the gene for the leptin receptor LEPR and the APOE-CI-CII cluster showed a significantly higher risk of coronary heart disease.¹ However, both variants were associated with lower levels of CRP (and, for the SNP in LEPR, lower body weight and body mass index), suggesting that the links with coronary heart disease are not mediated by CRP. These findings illustrate the ability of genome-wide association studies to identify novel susceptibility loci for complex disease without limiting investigation to genes previously thought to take part in coronary heart disease.

In view of the evidence from this study, it seems that the benefits accruing to patients with high CRP from lipid-lowering therapy as demonstrated in the JUPITER trial are likely not the result of CRP-lowering per se, but rather are the result of action on the underlying pathology that leads to elevation of inflammatory markers, including CRP. As an editorial accompanying the study by Elliot et al pointed out, the work not only provides important information in the effort to identify genetic markers associated with complex disease, but it also helps discern the role of the genes and their products in the progress and treatment of common diseases.³⁶

Subsequent studies of CRP and the “directionality” of its role in coronary disease,³⁷ as well as in other conditions such as obesity and cancer,^38,39 have carried on the strategy of Elliott et al, providing further evidence for the function of CRP as a bystander in the inflammatory response and complex disease progression.

IMPLICATIONS OF THESE FINDINGS

Tools now exist to leapfrog the randomized controlled trials that have been the primary way of examining the role of potential mediators of common diseases. Mendelian randomization aids in determining whether biomarkers are involved in disease pathogenesis, are simply bystanders, or are secondary markers caused by the disease itself. While randomized controlled trials will still be important, this new approach offers the power of evaluating much larger sample sizes and more equally stratifying confounding factors between study groups by relying on independent assortment of genetic traits.

In medical care today, the prevention of coronary heart disease entails aggressive treatment of hypertension and hyperlipidemia, along with lifestyle modifications such as balanced diet, routine exercise, and smoking cessation. Given the large numbers of patients at risk, even with low risk scores using currently identified risk factors, more specific and sensitive markers (or panels of such markers) of cardiovascular risk are needed.

In the personalized medicine of the future, we will rely on markers that not only identify people at higher risk, but also tell us who would benefit from certain therapies. From the JUPITER trial, we understand that patients with elevated CRP levels may be appropriate candidates for statin therapy even if they have normal levels of LDL-C.³⁶ The study by Elliott et al steers us away from using CRP-affecting SNPs in predicting the course of disease and also from the belief that targeting CRP alone would be a worthwhile therapeutic strategy.

The inflammatory hypothesis of coronary heart disease remains a very important area of investigation, and CRP may turn out to be one of the best biomarkers we have to predict the progression of coronary diseases. But the study by Elliott et al demonstrates that CRP-lowering drugs are unlikely to be magic bullets.

Most importantly, geneticists will partner with clinical researchers to answer important questions about biomarkers and genes, capitalizing on large sets of population data.

Genomics research is paying off, not only by identifying people at risk of rare inherited diseases but also by clarifying the pathogenic mechanisms of important, common ones.

Thanks to advances in technology, we can now, at a reasonable cost, simultaneously screen for millions of genetic variants in thousands of people to find variants that are more common in people with a given disease than without the disease, a fruitful method called a genome-wide association study. Moreover, an epidemiologic method called mendelian randomization takes advantage of the natural reshuffling of the genetic deck that occurs with each generation to give an estimate of whether certain gene products are mediators—or merely markers—of disease.

In a landmark study published in 2009, Elliott et al¹ used mendelian randomization to evaluate the role of C-reactive protein (CRP) in coronary artery disease.

Here, we review the use of genetic tools in a clinical context, highlighting CRP to illustrate some of the potential uses and limitations of applied genomics in clinical investigation.

NATURE VS NURTURE: AN AGE-OLD DEBATE

The relative contributions of genetic and environmental factors to human health and disease— nature vs nurture—is an age-old debate in which interest has been renewed in this era of intensive research in molecular genetics.

In the 19th century, Charles Darwin proposed that evolution proceeds through natural selection of variations in inherited traits. His contemporary, Gregor Mendel, showed that traits are inherited in discrete units, later named genes. Just what genes were and how they worked had to await the discovery of the structure of DNA in 1953, by Watson and Crick.²

Since then, progress has accelerated. Advances in recombinant DNA and DNA-sequencing technologies enabled sequencing of the entire human genome only 50 years later. More recently, we have seen automated rapid sequencing, the HapMap project (more on this below), and the advent of genome-wide association studies that uncover genetic variants correlated with or predisposing to common, complex human diseases.

Until recent years, medical genetics was mostly confined to the study of rare syndromes, such as Huntington disease, that are due either to a change in a single gene or to abnormal quantities of large swaths of chromosomes containing many genes. It had little application to most of the common disorders seen by primary care physicians. However, the genes and pathways implicated in rare monogenic disorders have provided key insights into common diseases. For example, defining the genes and mutations underlying familial hypercholesterolemia highlighted the role of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerotic disease.

3.4 BILLION BASE PAIRS, 23,000 GENES

The DNA molecule consists of two strings of the nucleotides guanine (G), cytosine (C), thymine (T), and adenine (A). The human genome contains about 3.4 billion of these nucleotides, also called base pairs, as they bind G to C and A to T across the length of the double helix of the DNA molecule.

Only about 2% of these 3.4 billion base pairs make up genes, ie, sequences that are transcribed into RNA and then translated into protein. Humans have only about 23,000 genes, which is less than in some plant species.

What about the rest of the human genome, ie, most of it? Previously dismissed as “junk,” these regions likely possess more elusive regulatory functions, controlling gene expression (ultimately, the production of protein), which varies considerably from tissue to tissue and over a person’s lifetime.

It is the orchestration of gene expression over time and cell type that gives the human body its intricate complexity. The study of how all our genes and gene products interact is called genomics and is part of the larger topic of the network of protein interactions (proteomics) and of the integration of various protein pathways (metabolomics).

We are all 99% identical—or 12 million nucleotides different

Human genome sequences are 99% identical across populations. But the remaining 1% is still a big number: there are more than 12 million variants between any two individuals’ genomes. These variants include:

• Single-nucleotide polymorphisms (SNPs), ie, a single-nucleotide change that is present in at least 1% of the population
• Copy number variants (CNVs), ie, a stretch of DNA that is either missing or duplicated
• Repeating patterns of DNA that vary in the number of repeated sequences.

THE EVOLUTION OF GENOMICS RESEARCH

Much of the initial focus of research in the genomics era consisted of identifying these variants and discovering associations between them and particular human diseases or clinical outcomes. In this way, we uncovered a multitude of potential new biomarkers and therapeutic targets, requiring further investigation into the connection between the DNA variant and the clinical state.

At the close of the 20th century, genetic factors were correlated with human disease by linkage analysis (a method of mapping patterns of markers that congregate in relatively narrow regions of DNA in families with specific diseases), and candidate gene approaches, whereby genes were investigated on the basis of their postulated biology and of previous studies. These techniques were relatively low-yield and cumbersome; years of work uncovered only a handful of genes proven to be associated with diseases.

Newer tools can look at scores of genes linked to common diseases. Researchers now rely on sophisticated DNA sequencing tools and interpretation software to sift masses of data to find meaningful markers (DNA variants or mutations).

Genomics research in the past few years has been mostly hypothesis-independent. Investigators are no longer limited to the small cache of genes whose corresponding proteins are well characterized, but can instead probe the entire genome for connections between our DNA and our physiology.

Over the past decade, much clinically useful information has been gathered in genome-wide association studies.

The rise of this type of study rested on our emerging understanding of the architecture of our genome. When the genomes of multiple humans were fully sequenced, we discovered that specific variants do not occur randomly in relation to each other. Rather, they tend to be inherited in particular blocks called haplotypes, and some SNPs or combinations of SNPS are very rare or essentially never seen.

In its first phase, the HapMap project organized these useful blocks of variants, genotyping 1 million SNPs for each of 270 individuals from mother-father-offspring trios from distinct geographic regions of the world.³ The second phase of the HapMap project extended the analysis to more than 3 million SNPs and to other populations.⁴

While the HapMap should be generally applicable to other populations not yet studied, limitations of the first two HapMap phases include rare SNPs or CNVs, or variants outside of haplotype regions.

The 1,000 Genomes Project, now under way, will develop an even more comprehensive catalog of human genetic variants in much broader populations.

The success of genome-wide association studies is also partly attributable to progress in DNA-sequencing technology. Using microarray chips, we can now look at millions of SNPs per patient or the entire coding sequence of the genome (termed the exome) in a single experiment that is both time-effecient and cost-effective.

What is a genome-wide association study?

A genome-wide association study generally compares genetic variants between patients with a particular clinical condition (cases) and people without the condition (controls), looking for statistically significant differences. As a tool for genetic discovery, these studies have revealed many avenues for further investigation in the pathogenesis of disease, as well as potential targets of therapy.

Using these studies, research groups around the world have found reproducible correlations between genetic variants and susceptibility to common adult-onset diseases.

Although many of the variants identified in these studies are associated with only a slightly higher risk of disease, the method is free of many of the inherent biases associated with clinical research. These studies permit a comprehensive, hypothesis-independent and unbiased scan of the genome to identify novel susceptibility factors, whereas earlier genetic epidemiology studies could take on only a handful of variables to evaluate at a time. Additionally, they are powered to detect very small increases (or decreases) in disease risk, previously outside the reach of linkage analysis. Polymorphisms (or, presumably, non-disease-causing DNA changes) discovered using these studies often correlate with clinical phenotypes or with levels of biomarkers, even if the genetic variants are not necessarily pathologic in themselves.

Thus, genome-wide association studies have led to important insights into the pathogenesis of multiple common diseases, such as inflammatory bowel disease and diabetes mellitus, and they are facilitating new treatment approaches. For instance, multiple studies have reproduced an association between Crohn disease and variation in the gene NOD2, whose protein product is implicated in bacterial product recognition, autophagy, and apoptosis.⁵ This discovery led to the investigation of new potential therapies for Crohn disease, ie, the tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva), known to inhibit NOD2 activity, and to the prognostic use of the NOD2 genotype in Crohn disease (a field of study known as genotype-phenotype correlation).

Future advances will likely come from looking at combinations of variants, which may carry a higher risk of disease than single variants.

CORONARY HEART DISEASE: FRESH INSIGHT INTO AN OLD PROBLEM

Cardiovascular disease accounts for 30% of deaths worldwide.⁶ Of all the cardiovascular disorders, coronary heart disease is rising most rapidly in incidence, as the rest of the world adopts Western practices such as a high-calorie, high-fat, high-glycemic diet.

Hundreds of risk factors for coronary heart disease have been described.⁷ Three of them are clearly modifiable participants in the pathogenesis of atherosclerosis: hypertension, smoking, and elevated LDL-C. These and others form the basis for risk-assessment tools such as the Framingham risk score and the Prospective Cardiovascular Münster (PROCAM) study score. Other possible markers require further evaluation as to whether they are clinically useful and are direct mediators of coronary heart disease.

Because up to 40% of coronary deaths occur in people who lack conventional risk factors for it (eg, they do not smoke and they have normal levels of LDL-C and blood pressure), researchers are searching hard for new, potentially treatable risk factors.⁸ Of particular interest are components of inflammatory pathways linked with atherosclerosis and coronary heart disease. The identity of the key inflammatory factors that cause arterial plaque formation and rupture continues to be studied.

CRP, an acute-phase reactant produced by the liver in response to inflammation, has received much attention, as serum CRP levels correlate strongly with coronary events. Researchers have used modifiers of CRP to try to alter the course of coronary heart disease, but traditional research has so far failed to establish a causal relationship between CRP and coronary heart disease.⁹

How we know that LDL-C is a mediator, not just a marker

As a risk factor, LDL-C resembles CRP in that its levels correlate with a number of other, confounding risk factors. Therefore, much basic research and clinical observation had to be done before we could say that LDL-C plays a role in the pathogenesis of coronary heart disease.

Initially an association between LDL-C and heart disease was noted.¹⁰ Then, studies of familial hypercholesterolemia uncovered genetic abnormalities that increase LDL-C levels and, thereby, the risk of coronary heart disease—eg, mutations in the LDL receptor gene,^11–14 the apolipoprotein B (APOB) gene at its LDL receptor-binding domain,¹⁵LDL-RAP1 (a gene encoding an accessory adaptor protein that interacts with the LDL receptor),¹⁶ and PCSK9 (a gene that codes for proprotein convertase subtilisin-kexin type 9 protease).¹⁷

Conversely, specific loss-of-function truncating mutations of PCSK9 that reduce LDL-C levels are associated with strong protection against coronary heart disease.¹⁸ Other gene mutations that reduce LDL-C also lower the risk.^19,20

Further, a genome-wide association study²¹ identified multiple genetic variations associated with different forms of dyslipidemia, uncovering additional links between LDL-C and coronary heart disease.

Finally, randomized controlled trials of niacin, fibrates, and statins showed that these potent LDL-C-lowering agents reduce the rate of development or progression of coronary heart disease.^22,23

Unlike LDL-C, no familial syndromes of coronary heart disease have been recognized in patients who have isolated high serum levels of CRP.

Since many substances in addition to CRP increase in concentration in both acute and chronic inflammatory states, agents that lower CRP in a targeted manner would be needed for large prospective, randomized trials to show whether CRP plays a direct role in coronary heart disease. A specific CRP inhibitor, 1,6-bis(phosphocholine)-hexane, may aid in these efforts, although it is not orally bioavailable and has a very short serum half-life.²⁴

The JUPITER trial. Statins lower levels of both LDL-C and CRP. The Justification for the Use of Statins in Primary Prevention: an Intervention Evaluating Rosuvastatin (JUPITER) trial was designed to find out whether statins alter coronary risk in patients with “normal” LDL-C levels (< 130 mg/dL) and elevated CRP levels (> 2 g/L).²⁵

In this prospective, randomized trial, statin treatment resulted in a dramatic risk reduction of 40% to 50% in multiple coronary end points, as well as a reduction in CRP levels of 37% compared with placebo. However, LDL-C levels fell by 50%, confounding the effect on CRP, as the lower coronary event rate could alternatively be explained by the effect of lower-than-normal LDL-C levels. Thus, a causative link between CRP and coronary heart disease could not be proved.²⁶

Though ongoing trials may further illuminate the role of inflammation in the development of coronary heart disease, and specific CRP inhibitors are in development, we have few tools to answer the fundamental question of whether CRP itself is an active participant in cardiovascular disease progression or if it is a bystander marker, helping to define risk for patients who develop coronary heart disease without other known risk factors.

Of note, adding CRP to the Framingham risk score does not improve its predictive power very much in any age group.^27,28 Nevertheless, for certain end points, such as the long-term rate of death after percutaneous coronary intervention²⁹ or of cardiovascular death immediately after coronary artery bypass grafting,³⁰ CRP levels predict coronary events reliably.

BIOMARKERS AND MENDELIAN RANDOMIZATION

Further insight into the CRP-coronary association may lie in the genes. Intriguingly, while mutations have been found that alter the serum concentration of CRP, these isolated changes in CRP levels have not yet been shown to affect heart disease risk.^9,31,32

If one were to design a prospective, interventional study to evaluate the role of CRP in coronary heart disease, it would be very difficult to tease apart the specific impact of CRP from that of other variables that are often present in people with high CRP, such as obesity and hyperlipidemia. The technique of mendelian randomization offers a way to evaluate the correlation between coronary heart disease development and CRP levels independent of other risk factors.

How many heart attacks in people with or without polymorphisms?

Mendelian randomization takes advantage of a basic genetic principle, ie, the independent assortment of traits. According to Mendel’s second law, alleles for different traits are inherited independently of one another. Therefore, the gene that encodes CRP and other genes that influence its circulating level are presumably inherited independently from other genes that influence coronary risk.

In typical studies of CRP, participants are grouped according to whether they have high or low CRP levels. In these studies, confounding variables congregate in these two groups. For example, people with high CRP may be more likely to smoke and to have a higher body mass index and higher lipid levels—all of which influence cardiovascular outcomes. It is therefore difficult to tease out the effect of CRP levels from other background risk factors.

In contrast, in studies using mendelian randomization, patients are grouped according to whether they have a variant that affects the substance being studied (eg, CRP), and outcomes are compared between the two genetic groups.

Strengths and limitations of this method

By randomizing research subjects by gene variants affecting CRP levels, it is theoretically possible to achieve more equal stratification and minimize confounding between subgroups.³³

Mendelian randomization should also address the possibility of “reverse causality,” when the intermediate trait with a potential role in disease development (eg, CRP) is actually regulated by the disease state itself (ie, “inflammation of atherosclerotic cardiovascular disease”).³⁴

A limitation of mendelian randomization is that different genes influencing the biomarker under investigation must be proven to be truly randomly assorted among populations. It cannot be assumed that levels of a biomarker are equally distributed across cases and controls when there may in fact be non-random genetic associations.

For instance, if SNPs in various genes that affect creatine kinase levels were being compared to cardiovascular outcome, it would be important to take into account that baseline creatine kinase levels are higher in African Americans as well as in men in interpreting the study data.³⁵

THE ELLIOTT STUDY (2009)

In a study published in 2009, Elliott et al¹ mined genome-wide data collected over the last decade to bring more clarity to the issue of causality between elevated CRP and heart disease.

To accomplish mendelian randomization, the authors assessed SNPs that affect circulating CRP levels in combined sets of 28,000 cases and 100,000 controls—robust population sizes. The SNP variants included were associated with approximately 20% lower CRP levels. This degree of CRP reduction should correspond to a 6% reduction in coronary risk as predicted by meta-analysis of observational studies.

The authors found significant associations between these SNPs and CRP levels and between CRP levels and coronary heart disease, but not between the SNPs and coronary disease when results for three SNPs were combined and standardized to a 20% lower CRP level (odds ratio 1.00, 95% confidence interval 0.97–1.02).¹

In view of the lack of association between coronary heart disease and SNPs that affect CRP levels, the authors suggested that the observational data linking CRP levels and coronary disease may have been confounded by other risk factors, or that the trend is due to reverse causation (the inflammatory response associated with atherosclerosis elevates CRP) rather than CRP’s directly causing heart disease.

These findings have important implications for management of cardiovascular disease, as therapeutic strategies to reduce plasma CRP levels are less likely to be beneficial.

The authors also described other genetic variants that may affect coronary heart disease. Carriers of minor alleles of SNPs in the gene for the leptin receptor LEPR and the APOE-CI-CII cluster showed a significantly higher risk of coronary heart disease.¹ However, both variants were associated with lower levels of CRP (and, for the SNP in LEPR, lower body weight and body mass index), suggesting that the links with coronary heart disease are not mediated by CRP. These findings illustrate the ability of genome-wide association studies to identify novel susceptibility loci for complex disease without limiting investigation to genes previously thought to take part in coronary heart disease.

In view of the evidence from this study, it seems that the benefits accruing to patients with high CRP from lipid-lowering therapy as demonstrated in the JUPITER trial are likely not the result of CRP-lowering per se, but rather are the result of action on the underlying pathology that leads to elevation of inflammatory markers, including CRP. As an editorial accompanying the study by Elliot et al pointed out, the work not only provides important information in the effort to identify genetic markers associated with complex disease, but it also helps discern the role of the genes and their products in the progress and treatment of common diseases.³⁶

Subsequent studies of CRP and the “directionality” of its role in coronary disease,³⁷ as well as in other conditions such as obesity and cancer,^38,39 have carried on the strategy of Elliott et al, providing further evidence for the function of CRP as a bystander in the inflammatory response and complex disease progression.

IMPLICATIONS OF THESE FINDINGS

Tools now exist to leapfrog the randomized controlled trials that have been the primary way of examining the role of potential mediators of common diseases. Mendelian randomization aids in determining whether biomarkers are involved in disease pathogenesis, are simply bystanders, or are secondary markers caused by the disease itself. While randomized controlled trials will still be important, this new approach offers the power of evaluating much larger sample sizes and more equally stratifying confounding factors between study groups by relying on independent assortment of genetic traits.

In medical care today, the prevention of coronary heart disease entails aggressive treatment of hypertension and hyperlipidemia, along with lifestyle modifications such as balanced diet, routine exercise, and smoking cessation. Given the large numbers of patients at risk, even with low risk scores using currently identified risk factors, more specific and sensitive markers (or panels of such markers) of cardiovascular risk are needed.

In the personalized medicine of the future, we will rely on markers that not only identify people at higher risk, but also tell us who would benefit from certain therapies. From the JUPITER trial, we understand that patients with elevated CRP levels may be appropriate candidates for statin therapy even if they have normal levels of LDL-C.³⁶ The study by Elliott et al steers us away from using CRP-affecting SNPs in predicting the course of disease and also from the belief that targeting CRP alone would be a worthwhile therapeutic strategy.

The inflammatory hypothesis of coronary heart disease remains a very important area of investigation, and CRP may turn out to be one of the best biomarkers we have to predict the progression of coronary diseases. But the study by Elliott et al demonstrates that CRP-lowering drugs are unlikely to be magic bullets.

Most importantly, geneticists will partner with clinical researchers to answer important questions about biomarkers and genes, capitalizing on large sets of population data.

Genomics research is paying off, not only by identifying people at risk of rare inherited diseases but also by clarifying the pathogenic mechanisms of important, common ones.

Thanks to advances in technology, we can now, at a reasonable cost, simultaneously screen for millions of genetic variants in thousands of people to find variants that are more common in people with a given disease than without the disease, a fruitful method called a genome-wide association study. Moreover, an epidemiologic method called mendelian randomization takes advantage of the natural reshuffling of the genetic deck that occurs with each generation to give an estimate of whether certain gene products are mediators—or merely markers—of disease.

In a landmark study published in 2009, Elliott et al¹ used mendelian randomization to evaluate the role of C-reactive protein (CRP) in coronary artery disease.

Here, we review the use of genetic tools in a clinical context, highlighting CRP to illustrate some of the potential uses and limitations of applied genomics in clinical investigation.

NATURE VS NURTURE: AN AGE-OLD DEBATE

The relative contributions of genetic and environmental factors to human health and disease— nature vs nurture—is an age-old debate in which interest has been renewed in this era of intensive research in molecular genetics.

In the 19th century, Charles Darwin proposed that evolution proceeds through natural selection of variations in inherited traits. His contemporary, Gregor Mendel, showed that traits are inherited in discrete units, later named genes. Just what genes were and how they worked had to await the discovery of the structure of DNA in 1953, by Watson and Crick.²

Since then, progress has accelerated. Advances in recombinant DNA and DNA-sequencing technologies enabled sequencing of the entire human genome only 50 years later. More recently, we have seen automated rapid sequencing, the HapMap project (more on this below), and the advent of genome-wide association studies that uncover genetic variants correlated with or predisposing to common, complex human diseases.

Until recent years, medical genetics was mostly confined to the study of rare syndromes, such as Huntington disease, that are due either to a change in a single gene or to abnormal quantities of large swaths of chromosomes containing many genes. It had little application to most of the common disorders seen by primary care physicians. However, the genes and pathways implicated in rare monogenic disorders have provided key insights into common diseases. For example, defining the genes and mutations underlying familial hypercholesterolemia highlighted the role of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerotic disease.

3.4 BILLION BASE PAIRS, 23,000 GENES

The DNA molecule consists of two strings of the nucleotides guanine (G), cytosine (C), thymine (T), and adenine (A). The human genome contains about 3.4 billion of these nucleotides, also called base pairs, as they bind G to C and A to T across the length of the double helix of the DNA molecule.

Only about 2% of these 3.4 billion base pairs make up genes, ie, sequences that are transcribed into RNA and then translated into protein. Humans have only about 23,000 genes, which is less than in some plant species.

What about the rest of the human genome, ie, most of it? Previously dismissed as “junk,” these regions likely possess more elusive regulatory functions, controlling gene expression (ultimately, the production of protein), which varies considerably from tissue to tissue and over a person’s lifetime.

It is the orchestration of gene expression over time and cell type that gives the human body its intricate complexity. The study of how all our genes and gene products interact is called genomics and is part of the larger topic of the network of protein interactions (proteomics) and of the integration of various protein pathways (metabolomics).

We are all 99% identical—or 12 million nucleotides different

Human genome sequences are 99% identical across populations. But the remaining 1% is still a big number: there are more than 12 million variants between any two individuals’ genomes. These variants include:

• Single-nucleotide polymorphisms (SNPs), ie, a single-nucleotide change that is present in at least 1% of the population
• Copy number variants (CNVs), ie, a stretch of DNA that is either missing or duplicated
• Repeating patterns of DNA that vary in the number of repeated sequences.

THE EVOLUTION OF GENOMICS RESEARCH

Much of the initial focus of research in the genomics era consisted of identifying these variants and discovering associations between them and particular human diseases or clinical outcomes. In this way, we uncovered a multitude of potential new biomarkers and therapeutic targets, requiring further investigation into the connection between the DNA variant and the clinical state.

At the close of the 20th century, genetic factors were correlated with human disease by linkage analysis (a method of mapping patterns of markers that congregate in relatively narrow regions of DNA in families with specific diseases), and candidate gene approaches, whereby genes were investigated on the basis of their postulated biology and of previous studies. These techniques were relatively low-yield and cumbersome; years of work uncovered only a handful of genes proven to be associated with diseases.

Newer tools can look at scores of genes linked to common diseases. Researchers now rely on sophisticated DNA sequencing tools and interpretation software to sift masses of data to find meaningful markers (DNA variants or mutations).

Genomics research in the past few years has been mostly hypothesis-independent. Investigators are no longer limited to the small cache of genes whose corresponding proteins are well characterized, but can instead probe the entire genome for connections between our DNA and our physiology.

Over the past decade, much clinically useful information has been gathered in genome-wide association studies.

The rise of this type of study rested on our emerging understanding of the architecture of our genome. When the genomes of multiple humans were fully sequenced, we discovered that specific variants do not occur randomly in relation to each other. Rather, they tend to be inherited in particular blocks called haplotypes, and some SNPs or combinations of SNPS are very rare or essentially never seen.

In its first phase, the HapMap project organized these useful blocks of variants, genotyping 1 million SNPs for each of 270 individuals from mother-father-offspring trios from distinct geographic regions of the world.³ The second phase of the HapMap project extended the analysis to more than 3 million SNPs and to other populations.⁴

While the HapMap should be generally applicable to other populations not yet studied, limitations of the first two HapMap phases include rare SNPs or CNVs, or variants outside of haplotype regions.

The 1,000 Genomes Project, now under way, will develop an even more comprehensive catalog of human genetic variants in much broader populations.

The success of genome-wide association studies is also partly attributable to progress in DNA-sequencing technology. Using microarray chips, we can now look at millions of SNPs per patient or the entire coding sequence of the genome (termed the exome) in a single experiment that is both time-effecient and cost-effective.

What is a genome-wide association study?

A genome-wide association study generally compares genetic variants between patients with a particular clinical condition (cases) and people without the condition (controls), looking for statistically significant differences. As a tool for genetic discovery, these studies have revealed many avenues for further investigation in the pathogenesis of disease, as well as potential targets of therapy.

Using these studies, research groups around the world have found reproducible correlations between genetic variants and susceptibility to common adult-onset diseases.

Although many of the variants identified in these studies are associated with only a slightly higher risk of disease, the method is free of many of the inherent biases associated with clinical research. These studies permit a comprehensive, hypothesis-independent and unbiased scan of the genome to identify novel susceptibility factors, whereas earlier genetic epidemiology studies could take on only a handful of variables to evaluate at a time. Additionally, they are powered to detect very small increases (or decreases) in disease risk, previously outside the reach of linkage analysis. Polymorphisms (or, presumably, non-disease-causing DNA changes) discovered using these studies often correlate with clinical phenotypes or with levels of biomarkers, even if the genetic variants are not necessarily pathologic in themselves.

Thus, genome-wide association studies have led to important insights into the pathogenesis of multiple common diseases, such as inflammatory bowel disease and diabetes mellitus, and they are facilitating new treatment approaches. For instance, multiple studies have reproduced an association between Crohn disease and variation in the gene NOD2, whose protein product is implicated in bacterial product recognition, autophagy, and apoptosis.⁵ This discovery led to the investigation of new potential therapies for Crohn disease, ie, the tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva), known to inhibit NOD2 activity, and to the prognostic use of the NOD2 genotype in Crohn disease (a field of study known as genotype-phenotype correlation).

Future advances will likely come from looking at combinations of variants, which may carry a higher risk of disease than single variants.

CORONARY HEART DISEASE: FRESH INSIGHT INTO AN OLD PROBLEM

Cardiovascular disease accounts for 30% of deaths worldwide.⁶ Of all the cardiovascular disorders, coronary heart disease is rising most rapidly in incidence, as the rest of the world adopts Western practices such as a high-calorie, high-fat, high-glycemic diet.

Hundreds of risk factors for coronary heart disease have been described.⁷ Three of them are clearly modifiable participants in the pathogenesis of atherosclerosis: hypertension, smoking, and elevated LDL-C. These and others form the basis for risk-assessment tools such as the Framingham risk score and the Prospective Cardiovascular Münster (PROCAM) study score. Other possible markers require further evaluation as to whether they are clinically useful and are direct mediators of coronary heart disease.

Because up to 40% of coronary deaths occur in people who lack conventional risk factors for it (eg, they do not smoke and they have normal levels of LDL-C and blood pressure), researchers are searching hard for new, potentially treatable risk factors.⁸ Of particular interest are components of inflammatory pathways linked with atherosclerosis and coronary heart disease. The identity of the key inflammatory factors that cause arterial plaque formation and rupture continues to be studied.

CRP, an acute-phase reactant produced by the liver in response to inflammation, has received much attention, as serum CRP levels correlate strongly with coronary events. Researchers have used modifiers of CRP to try to alter the course of coronary heart disease, but traditional research has so far failed to establish a causal relationship between CRP and coronary heart disease.⁹

How we know that LDL-C is a mediator, not just a marker

As a risk factor, LDL-C resembles CRP in that its levels correlate with a number of other, confounding risk factors. Therefore, much basic research and clinical observation had to be done before we could say that LDL-C plays a role in the pathogenesis of coronary heart disease.

Initially an association between LDL-C and heart disease was noted.¹⁰ Then, studies of familial hypercholesterolemia uncovered genetic abnormalities that increase LDL-C levels and, thereby, the risk of coronary heart disease—eg, mutations in the LDL receptor gene,^11–14 the apolipoprotein B (APOB) gene at its LDL receptor-binding domain,¹⁵LDL-RAP1 (a gene encoding an accessory adaptor protein that interacts with the LDL receptor),¹⁶ and PCSK9 (a gene that codes for proprotein convertase subtilisin-kexin type 9 protease).¹⁷

Conversely, specific loss-of-function truncating mutations of PCSK9 that reduce LDL-C levels are associated with strong protection against coronary heart disease.¹⁸ Other gene mutations that reduce LDL-C also lower the risk.^19,20

Further, a genome-wide association study²¹ identified multiple genetic variations associated with different forms of dyslipidemia, uncovering additional links between LDL-C and coronary heart disease.

Finally, randomized controlled trials of niacin, fibrates, and statins showed that these potent LDL-C-lowering agents reduce the rate of development or progression of coronary heart disease.^22,23

Unlike LDL-C, no familial syndromes of coronary heart disease have been recognized in patients who have isolated high serum levels of CRP.

Since many substances in addition to CRP increase in concentration in both acute and chronic inflammatory states, agents that lower CRP in a targeted manner would be needed for large prospective, randomized trials to show whether CRP plays a direct role in coronary heart disease. A specific CRP inhibitor, 1,6-bis(phosphocholine)-hexane, may aid in these efforts, although it is not orally bioavailable and has a very short serum half-life.²⁴

The JUPITER trial. Statins lower levels of both LDL-C and CRP. The Justification for the Use of Statins in Primary Prevention: an Intervention Evaluating Rosuvastatin (JUPITER) trial was designed to find out whether statins alter coronary risk in patients with “normal” LDL-C levels (< 130 mg/dL) and elevated CRP levels (> 2 g/L).²⁵

In this prospective, randomized trial, statin treatment resulted in a dramatic risk reduction of 40% to 50% in multiple coronary end points, as well as a reduction in CRP levels of 37% compared with placebo. However, LDL-C levels fell by 50%, confounding the effect on CRP, as the lower coronary event rate could alternatively be explained by the effect of lower-than-normal LDL-C levels. Thus, a causative link between CRP and coronary heart disease could not be proved.²⁶

Though ongoing trials may further illuminate the role of inflammation in the development of coronary heart disease, and specific CRP inhibitors are in development, we have few tools to answer the fundamental question of whether CRP itself is an active participant in cardiovascular disease progression or if it is a bystander marker, helping to define risk for patients who develop coronary heart disease without other known risk factors.

Of note, adding CRP to the Framingham risk score does not improve its predictive power very much in any age group.^27,28 Nevertheless, for certain end points, such as the long-term rate of death after percutaneous coronary intervention²⁹ or of cardiovascular death immediately after coronary artery bypass grafting,³⁰ CRP levels predict coronary events reliably.

BIOMARKERS AND MENDELIAN RANDOMIZATION

Further insight into the CRP-coronary association may lie in the genes. Intriguingly, while mutations have been found that alter the serum concentration of CRP, these isolated changes in CRP levels have not yet been shown to affect heart disease risk.^9,31,32

If one were to design a prospective, interventional study to evaluate the role of CRP in coronary heart disease, it would be very difficult to tease apart the specific impact of CRP from that of other variables that are often present in people with high CRP, such as obesity and hyperlipidemia. The technique of mendelian randomization offers a way to evaluate the correlation between coronary heart disease development and CRP levels independent of other risk factors.

How many heart attacks in people with or without polymorphisms?

Mendelian randomization takes advantage of a basic genetic principle, ie, the independent assortment of traits. According to Mendel’s second law, alleles for different traits are inherited independently of one another. Therefore, the gene that encodes CRP and other genes that influence its circulating level are presumably inherited independently from other genes that influence coronary risk.

In typical studies of CRP, participants are grouped according to whether they have high or low CRP levels. In these studies, confounding variables congregate in these two groups. For example, people with high CRP may be more likely to smoke and to have a higher body mass index and higher lipid levels—all of which influence cardiovascular outcomes. It is therefore difficult to tease out the effect of CRP levels from other background risk factors.

In contrast, in studies using mendelian randomization, patients are grouped according to whether they have a variant that affects the substance being studied (eg, CRP), and outcomes are compared between the two genetic groups.

Strengths and limitations of this method

By randomizing research subjects by gene variants affecting CRP levels, it is theoretically possible to achieve more equal stratification and minimize confounding between subgroups.³³

Mendelian randomization should also address the possibility of “reverse causality,” when the intermediate trait with a potential role in disease development (eg, CRP) is actually regulated by the disease state itself (ie, “inflammation of atherosclerotic cardiovascular disease”).³⁴

A limitation of mendelian randomization is that different genes influencing the biomarker under investigation must be proven to be truly randomly assorted among populations. It cannot be assumed that levels of a biomarker are equally distributed across cases and controls when there may in fact be non-random genetic associations.

For instance, if SNPs in various genes that affect creatine kinase levels were being compared to cardiovascular outcome, it would be important to take into account that baseline creatine kinase levels are higher in African Americans as well as in men in interpreting the study data.³⁵

THE ELLIOTT STUDY (2009)

In a study published in 2009, Elliott et al¹ mined genome-wide data collected over the last decade to bring more clarity to the issue of causality between elevated CRP and heart disease.

To accomplish mendelian randomization, the authors assessed SNPs that affect circulating CRP levels in combined sets of 28,000 cases and 100,000 controls—robust population sizes. The SNP variants included were associated with approximately 20% lower CRP levels. This degree of CRP reduction should correspond to a 6% reduction in coronary risk as predicted by meta-analysis of observational studies.

The authors found significant associations between these SNPs and CRP levels and between CRP levels and coronary heart disease, but not between the SNPs and coronary disease when results for three SNPs were combined and standardized to a 20% lower CRP level (odds ratio 1.00, 95% confidence interval 0.97–1.02).¹

In view of the lack of association between coronary heart disease and SNPs that affect CRP levels, the authors suggested that the observational data linking CRP levels and coronary disease may have been confounded by other risk factors, or that the trend is due to reverse causation (the inflammatory response associated with atherosclerosis elevates CRP) rather than CRP’s directly causing heart disease.

These findings have important implications for management of cardiovascular disease, as therapeutic strategies to reduce plasma CRP levels are less likely to be beneficial.

The authors also described other genetic variants that may affect coronary heart disease. Carriers of minor alleles of SNPs in the gene for the leptin receptor LEPR and the APOE-CI-CII cluster showed a significantly higher risk of coronary heart disease.¹ However, both variants were associated with lower levels of CRP (and, for the SNP in LEPR, lower body weight and body mass index), suggesting that the links with coronary heart disease are not mediated by CRP. These findings illustrate the ability of genome-wide association studies to identify novel susceptibility loci for complex disease without limiting investigation to genes previously thought to take part in coronary heart disease.

In view of the evidence from this study, it seems that the benefits accruing to patients with high CRP from lipid-lowering therapy as demonstrated in the JUPITER trial are likely not the result of CRP-lowering per se, but rather are the result of action on the underlying pathology that leads to elevation of inflammatory markers, including CRP. As an editorial accompanying the study by Elliot et al pointed out, the work not only provides important information in the effort to identify genetic markers associated with complex disease, but it also helps discern the role of the genes and their products in the progress and treatment of common diseases.³⁶

Subsequent studies of CRP and the “directionality” of its role in coronary disease,³⁷ as well as in other conditions such as obesity and cancer,^38,39 have carried on the strategy of Elliott et al, providing further evidence for the function of CRP as a bystander in the inflammatory response and complex disease progression.

IMPLICATIONS OF THESE FINDINGS

Tools now exist to leapfrog the randomized controlled trials that have been the primary way of examining the role of potential mediators of common diseases. Mendelian randomization aids in determining whether biomarkers are involved in disease pathogenesis, are simply bystanders, or are secondary markers caused by the disease itself. While randomized controlled trials will still be important, this new approach offers the power of evaluating much larger sample sizes and more equally stratifying confounding factors between study groups by relying on independent assortment of genetic traits.

In medical care today, the prevention of coronary heart disease entails aggressive treatment of hypertension and hyperlipidemia, along with lifestyle modifications such as balanced diet, routine exercise, and smoking cessation. Given the large numbers of patients at risk, even with low risk scores using currently identified risk factors, more specific and sensitive markers (or panels of such markers) of cardiovascular risk are needed.

In the personalized medicine of the future, we will rely on markers that not only identify people at higher risk, but also tell us who would benefit from certain therapies. From the JUPITER trial, we understand that patients with elevated CRP levels may be appropriate candidates for statin therapy even if they have normal levels of LDL-C.³⁶ The study by Elliott et al steers us away from using CRP-affecting SNPs in predicting the course of disease and also from the belief that targeting CRP alone would be a worthwhile therapeutic strategy.

The inflammatory hypothesis of coronary heart disease remains a very important area of investigation, and CRP may turn out to be one of the best biomarkers we have to predict the progression of coronary diseases. But the study by Elliott et al demonstrates that CRP-lowering drugs are unlikely to be magic bullets.

Most importantly, geneticists will partner with clinical researchers to answer important questions about biomarkers and genes, capitalizing on large sets of population data.

In the article “Presumed premature ventricular contractions” by Drs. Moises Auron and Donald Underwood (Cleve Clin J Med 2011; 78:812–813), Figure 1 was incorrectly labelled. The corrected figure and legend appear below. The authors wish to thank Philippe Akhrass, MD, from the State University of New York, Brooklyn, and Shahrokh Rafii, MD, from Brookdale University Hospital and Medical Center, Brooklyn, NY, for pointing out this error.

In the article “Presumed premature ventricular contractions” by Drs. Moises Auron and Donald Underwood (Cleve Clin J Med 2011; 78:812–813), Figure 1 was incorrectly labelled. The corrected figure and legend appear below. The authors wish to thank Philippe Akhrass, MD, from the State University of New York, Brooklyn, and Shahrokh Rafii, MD, from Brookdale University Hospital and Medical Center, Brooklyn, NY, for pointing out this error.

In the article “Presumed premature ventricular contractions” by Drs. Moises Auron and Donald Underwood (Cleve Clin J Med 2011; 78:812–813), Figure 1 was incorrectly labelled. The corrected figure and legend appear below. The authors wish to thank Philippe Akhrass, MD, from the State University of New York, Brooklyn, and Shahrokh Rafii, MD, from Brookdale University Hospital and Medical Center, Brooklyn, NY, for pointing out this error.

In Reply: We thank Dr. Keller for his excellent comment. The rationale for discontinuing screening in a woman over 70 who has multiple sexual partners without a history of an abnormal Pap test is that she is at lower risk of new-onset cervical intraepithelial neoplasia (CIN) than a younger woman because of her decreased rate of metaplasia and less accessible transformation zone. In addition, postmenopausal mucosal atrophy may predispose to false-positive cytology. False-positive results are likely to be followed by additional invasive procedures, anxiety, and cost to the patient. However, she is still at risk for acquiring human papillomavirus (HPV) and CIN. Given that cervical cancer develops slowly and risk factors decrease with age, it is reasonable to stop screening at this point. Also, the recommendation of the 3-year screening interval in women over 30 with multiple sexual partners who had negative Pap and HPV tests is based on the fact that they can acquire HPV the day after screening and subsequently develop CIN, but we can detect HPV and CIN in the next round of screening (3 years later) and so will not miss the opportunity to treat cervical dysplasia.

However, practice guidelines are never meant to replace a physician’s sound clinical decision made on an individual basis.

In Reply: We thank Dr. Keller for his excellent comment. The rationale for discontinuing screening in a woman over 70 who has multiple sexual partners without a history of an abnormal Pap test is that she is at lower risk of new-onset cervical intraepithelial neoplasia (CIN) than a younger woman because of her decreased rate of metaplasia and less accessible transformation zone. In addition, postmenopausal mucosal atrophy may predispose to false-positive cytology. False-positive results are likely to be followed by additional invasive procedures, anxiety, and cost to the patient. However, she is still at risk for acquiring human papillomavirus (HPV) and CIN. Given that cervical cancer develops slowly and risk factors decrease with age, it is reasonable to stop screening at this point. Also, the recommendation of the 3-year screening interval in women over 30 with multiple sexual partners who had negative Pap and HPV tests is based on the fact that they can acquire HPV the day after screening and subsequently develop CIN, but we can detect HPV and CIN in the next round of screening (3 years later) and so will not miss the opportunity to treat cervical dysplasia.

However, practice guidelines are never meant to replace a physician’s sound clinical decision made on an individual basis.

In Reply: We thank Dr. Keller for his excellent comment. The rationale for discontinuing screening in a woman over 70 who has multiple sexual partners without a history of an abnormal Pap test is that she is at lower risk of new-onset cervical intraepithelial neoplasia (CIN) than a younger woman because of her decreased rate of metaplasia and less accessible transformation zone. In addition, postmenopausal mucosal atrophy may predispose to false-positive cytology. False-positive results are likely to be followed by additional invasive procedures, anxiety, and cost to the patient. However, she is still at risk for acquiring human papillomavirus (HPV) and CIN. Given that cervical cancer develops slowly and risk factors decrease with age, it is reasonable to stop screening at this point. Also, the recommendation of the 3-year screening interval in women over 30 with multiple sexual partners who had negative Pap and HPV tests is based on the fact that they can acquire HPV the day after screening and subsequently develop CIN, but we can detect HPV and CIN in the next round of screening (3 years later) and so will not miss the opportunity to treat cervical dysplasia.

However, practice guidelines are never meant to replace a physician’s sound clinical decision made on an individual basis.

To the Editor: In their response to a letter to the editor (December 2011), Drs. Wartak and Bartholomew suggested the use of recombinant activated factor VIIa (NovoSeven) for bleeding in patients on dabigatran. They based this recommendation on a review by Stangier and Clemens,¹ which was based on phase II and III data on the efficacy and safety of dabigatran. There have been no controlled trials or prospective data on the use of this agent for this indication, nor are there data on its use in bleeding after intracranial hemorrhage, bleeding related to cardiac surgery, or trauma-related bleeding. In a systematic review, Yank et al² found that there is no lower mortality rate and an increased risk of thromboembolism when activated factor VIIa is used off-label. This agent is approved for use only in patients with hemophilia, and in fact Novo Nordisk paid a $25 million settlement for off-label promotion of this drug for nonapproved indications.³ Recombinant factor VIIa costs up to $10,000 per vial, and if it is used off-label, that cost is not reimbursed to the hospital.

Just because we can do something does not mean that we should do it. The use of recombinant factor VIIa for dabigatran-related bleeding needs to be studied in a controlled trial before it is routinely used. As seen in the cited review, indication drift can lead to adverse patient outcomes and will certainly lead to financial peril in hospitals across the country.

To the Editor: In their response to a letter to the editor (December 2011), Drs. Wartak and Bartholomew suggested the use of recombinant activated factor VIIa (NovoSeven) for bleeding in patients on dabigatran. They based this recommendation on a review by Stangier and Clemens,¹ which was based on phase II and III data on the efficacy and safety of dabigatran. There have been no controlled trials or prospective data on the use of this agent for this indication, nor are there data on its use in bleeding after intracranial hemorrhage, bleeding related to cardiac surgery, or trauma-related bleeding. In a systematic review, Yank et al² found that there is no lower mortality rate and an increased risk of thromboembolism when activated factor VIIa is used off-label. This agent is approved for use only in patients with hemophilia, and in fact Novo Nordisk paid a $25 million settlement for off-label promotion of this drug for nonapproved indications.³ Recombinant factor VIIa costs up to $10,000 per vial, and if it is used off-label, that cost is not reimbursed to the hospital.

Just because we can do something does not mean that we should do it. The use of recombinant factor VIIa for dabigatran-related bleeding needs to be studied in a controlled trial before it is routinely used. As seen in the cited review, indication drift can lead to adverse patient outcomes and will certainly lead to financial peril in hospitals across the country.

To the Editor: In their response to a letter to the editor (December 2011), Drs. Wartak and Bartholomew suggested the use of recombinant activated factor VIIa (NovoSeven) for bleeding in patients on dabigatran. They based this recommendation on a review by Stangier and Clemens,¹ which was based on phase II and III data on the efficacy and safety of dabigatran. There have been no controlled trials or prospective data on the use of this agent for this indication, nor are there data on its use in bleeding after intracranial hemorrhage, bleeding related to cardiac surgery, or trauma-related bleeding. In a systematic review, Yank et al² found that there is no lower mortality rate and an increased risk of thromboembolism when activated factor VIIa is used off-label. This agent is approved for use only in patients with hemophilia, and in fact Novo Nordisk paid a $25 million settlement for off-label promotion of this drug for nonapproved indications.³ Recombinant factor VIIa costs up to $10,000 per vial, and if it is used off-label, that cost is not reimbursed to the hospital.

Just because we can do something does not mean that we should do it. The use of recombinant factor VIIa for dabigatran-related bleeding needs to be studied in a controlled trial before it is routinely used. As seen in the cited review, indication drift can lead to adverse patient outcomes and will certainly lead to financial peril in hospitals across the country.

Researchers advise physicians to discuss the risks with women who have epilepsy and are of childbearing potential.

BALTIMORE—Fetal exposure to the antiepileptic drug (AED) valproate increases a child’s risk of autism and impairs his or her IQ until the age of 6, according to two studies presented at the 65th Annual Meeting of the American Epilepsy Society.

Children born to mothers on valproate monotherapy have a risk of childhood autism that is five times greater than that of children without prenatal exposure to the drug. In addition, children’s IQs are negatively associated with valproate dose, but not with carbamazepine, lamotrigine, or phenytoin.

Increased Risk of Autism
Previous research in animals and small studies involving humans have suggested that valproate treatment during pregnancy was associated with an increased risk of autism in the child.

To investigate this link, Jakob Christensen, PhD, a consultant neurologist at Aarhus University Hospital in Denmark, carried out a population-based cohort study. Using the Danish Civil Registration System, he identified 655,691 children born to 428,431 mothers between 1996 and 2006.
He looked to the Danish Prescription Register to identify women who had filled prescriptions for valproate from 30 days before the estimated date of conception to the day of birth.

Dr. Christensen also used the Danish Psychiatric Register to identify children diagnosed with an autism spectrum disorder and focused particularly on the subgroup that had been diagnosed with childhood autism. He and his colleagues then estimated the risk of autism in children born to mothers who used valproate during pregnancy and adjusted the risk estimates for parental psychiatric history, maternal age, and gender of the child.

Children born after prenatal exposure to valproate had more than twice the risk of an autism spectrum disorder than those without such exposure, according to the investigators. The risk of an autism spectrum disorder was 2.6 following valproate monotherapy and 2.5 following valproate polytherapy. The risk of childhood autism in children with prenatal exposure to valproate was 4.1 following valproate monotherapy and 6.8 following valproate polytherapy.

"Stopping any anticonvulsant medication poses a danger,” Dr. Christensen commented. “Women taking valproate who are contemplating pregnancy should consult with their doctors about the possibility of transitioning to another drug or reducing the dosage of their present medication when that isn’t possible.”

NeurodevelopmentalEffects of AEDs
Kimford Meador, MD, Director of the Emory Epilepsy Center and Professor of Neurology at Emory University in Atlanta, has directed the Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study. His preliminary analysis indicated that fetal exposure to valproate impaired children’s IQ at age 3. Dr. Meador and his colleagues conducted a new analysis to determine whether valproate’s effects on IQ continued until age 6.

The NEAD study enrolled pregnant women with epilepsy on AED monotherapy from 1999 to 2004. It aims to examine the long-term neurodevelopmental effects of four common AEDs: carbamazepine, lamotrigine, phenytoin, and valproate. The primary outcome for Dr. Meador’s new analysis was IQ at age 6, as measured by the Differential Ability Scale (DAS). The team also performed a secondary analysis of verbal and nonverbal cluster scores from the DAS. The sample size was 310 children.

Dr. Meador found that child IQ was lower with valproate exposure than it was with exposure to any of the other AEDs. The adjusted mean IQ for children born after valproate exposure was 97. By contrast, the adjusted mean IQ for carbamazepine was 105, the adjusted mean IQ for lamotrigine was 108, and the adjusted mean IQ for phenytoin was 108. The verbal cluster score was less than the nonverbal cluster score for lamotrigine and valproate.

In children born after fetal exposure to valproate, the risks of low IQ and decreased verbal and nonverbal abilities are dose-dependent. However, “the dose-dependent effect is not seen with other AEDs on any of these factors,” said Dr. Meador.

Women of childbearing potential need to understand the risks that valproate entails, said Dr. Meador. “In my mind, it’s a very poor first choice for women of childbearing potential.

“The quandary is that there’s a subgroup of women with primary generalized epilepsy who will only respond to valproate,” he added. “Because it is not possible to predict which women are in this category, neurologists should treat them with another AED before trying valproate,” said Dr. Meador.

To hear an audiocast related to this news article, please click here.

Researchers advise physicians to discuss the risks with women who have epilepsy and are of childbearing potential.

BALTIMORE—Fetal exposure to the antiepileptic drug (AED) valproate increases a child’s risk of autism and impairs his or her IQ until the age of 6, according to two studies presented at the 65th Annual Meeting of the American Epilepsy Society.

Children born to mothers on valproate monotherapy have a risk of childhood autism that is five times greater than that of children without prenatal exposure to the drug. In addition, children’s IQs are negatively associated with valproate dose, but not with carbamazepine, lamotrigine, or phenytoin.

Increased Risk of Autism
Previous research in animals and small studies involving humans have suggested that valproate treatment during pregnancy was associated with an increased risk of autism in the child.

To investigate this link, Jakob Christensen, PhD, a consultant neurologist at Aarhus University Hospital in Denmark, carried out a population-based cohort study. Using the Danish Civil Registration System, he identified 655,691 children born to 428,431 mothers between 1996 and 2006.
He looked to the Danish Prescription Register to identify women who had filled prescriptions for valproate from 30 days before the estimated date of conception to the day of birth.

Dr. Christensen also used the Danish Psychiatric Register to identify children diagnosed with an autism spectrum disorder and focused particularly on the subgroup that had been diagnosed with childhood autism. He and his colleagues then estimated the risk of autism in children born to mothers who used valproate during pregnancy and adjusted the risk estimates for parental psychiatric history, maternal age, and gender of the child.

Children born after prenatal exposure to valproate had more than twice the risk of an autism spectrum disorder than those without such exposure, according to the investigators. The risk of an autism spectrum disorder was 2.6 following valproate monotherapy and 2.5 following valproate polytherapy. The risk of childhood autism in children with prenatal exposure to valproate was 4.1 following valproate monotherapy and 6.8 following valproate polytherapy.

"Stopping any anticonvulsant medication poses a danger,” Dr. Christensen commented. “Women taking valproate who are contemplating pregnancy should consult with their doctors about the possibility of transitioning to another drug or reducing the dosage of their present medication when that isn’t possible.”

NeurodevelopmentalEffects of AEDs
Kimford Meador, MD, Director of the Emory Epilepsy Center and Professor of Neurology at Emory University in Atlanta, has directed the Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study. His preliminary analysis indicated that fetal exposure to valproate impaired children’s IQ at age 3. Dr. Meador and his colleagues conducted a new analysis to determine whether valproate’s effects on IQ continued until age 6.

The NEAD study enrolled pregnant women with epilepsy on AED monotherapy from 1999 to 2004. It aims to examine the long-term neurodevelopmental effects of four common AEDs: carbamazepine, lamotrigine, phenytoin, and valproate. The primary outcome for Dr. Meador’s new analysis was IQ at age 6, as measured by the Differential Ability Scale (DAS). The team also performed a secondary analysis of verbal and nonverbal cluster scores from the DAS. The sample size was 310 children.

Dr. Meador found that child IQ was lower with valproate exposure than it was with exposure to any of the other AEDs. The adjusted mean IQ for children born after valproate exposure was 97. By contrast, the adjusted mean IQ for carbamazepine was 105, the adjusted mean IQ for lamotrigine was 108, and the adjusted mean IQ for phenytoin was 108. The verbal cluster score was less than the nonverbal cluster score for lamotrigine and valproate.

In children born after fetal exposure to valproate, the risks of low IQ and decreased verbal and nonverbal abilities are dose-dependent. However, “the dose-dependent effect is not seen with other AEDs on any of these factors,” said Dr. Meador.

Women of childbearing potential need to understand the risks that valproate entails, said Dr. Meador. “In my mind, it’s a very poor first choice for women of childbearing potential.

“The quandary is that there’s a subgroup of women with primary generalized epilepsy who will only respond to valproate,” he added. “Because it is not possible to predict which women are in this category, neurologists should treat them with another AED before trying valproate,” said Dr. Meador.

To hear an audiocast related to this news article, please click here.

Researchers advise physicians to discuss the risks with women who have epilepsy and are of childbearing potential.

BALTIMORE—Fetal exposure to the antiepileptic drug (AED) valproate increases a child’s risk of autism and impairs his or her IQ until the age of 6, according to two studies presented at the 65th Annual Meeting of the American Epilepsy Society.

Children born to mothers on valproate monotherapy have a risk of childhood autism that is five times greater than that of children without prenatal exposure to the drug. In addition, children’s IQs are negatively associated with valproate dose, but not with carbamazepine, lamotrigine, or phenytoin.

Increased Risk of Autism
Previous research in animals and small studies involving humans have suggested that valproate treatment during pregnancy was associated with an increased risk of autism in the child.

To investigate this link, Jakob Christensen, PhD, a consultant neurologist at Aarhus University Hospital in Denmark, carried out a population-based cohort study. Using the Danish Civil Registration System, he identified 655,691 children born to 428,431 mothers between 1996 and 2006.
He looked to the Danish Prescription Register to identify women who had filled prescriptions for valproate from 30 days before the estimated date of conception to the day of birth.

Dr. Christensen also used the Danish Psychiatric Register to identify children diagnosed with an autism spectrum disorder and focused particularly on the subgroup that had been diagnosed with childhood autism. He and his colleagues then estimated the risk of autism in children born to mothers who used valproate during pregnancy and adjusted the risk estimates for parental psychiatric history, maternal age, and gender of the child.

Children born after prenatal exposure to valproate had more than twice the risk of an autism spectrum disorder than those without such exposure, according to the investigators. The risk of an autism spectrum disorder was 2.6 following valproate monotherapy and 2.5 following valproate polytherapy. The risk of childhood autism in children with prenatal exposure to valproate was 4.1 following valproate monotherapy and 6.8 following valproate polytherapy.

"Stopping any anticonvulsant medication poses a danger,” Dr. Christensen commented. “Women taking valproate who are contemplating pregnancy should consult with their doctors about the possibility of transitioning to another drug or reducing the dosage of their present medication when that isn’t possible.”

NeurodevelopmentalEffects of AEDs
Kimford Meador, MD, Director of the Emory Epilepsy Center and Professor of Neurology at Emory University in Atlanta, has directed the Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study. His preliminary analysis indicated that fetal exposure to valproate impaired children’s IQ at age 3. Dr. Meador and his colleagues conducted a new analysis to determine whether valproate’s effects on IQ continued until age 6.

The NEAD study enrolled pregnant women with epilepsy on AED monotherapy from 1999 to 2004. It aims to examine the long-term neurodevelopmental effects of four common AEDs: carbamazepine, lamotrigine, phenytoin, and valproate. The primary outcome for Dr. Meador’s new analysis was IQ at age 6, as measured by the Differential Ability Scale (DAS). The team also performed a secondary analysis of verbal and nonverbal cluster scores from the DAS. The sample size was 310 children.

Dr. Meador found that child IQ was lower with valproate exposure than it was with exposure to any of the other AEDs. The adjusted mean IQ for children born after valproate exposure was 97. By contrast, the adjusted mean IQ for carbamazepine was 105, the adjusted mean IQ for lamotrigine was 108, and the adjusted mean IQ for phenytoin was 108. The verbal cluster score was less than the nonverbal cluster score for lamotrigine and valproate.

In children born after fetal exposure to valproate, the risks of low IQ and decreased verbal and nonverbal abilities are dose-dependent. However, “the dose-dependent effect is not seen with other AEDs on any of these factors,” said Dr. Meador.

Women of childbearing potential need to understand the risks that valproate entails, said Dr. Meador. “In my mind, it’s a very poor first choice for women of childbearing potential.

“The quandary is that there’s a subgroup of women with primary generalized epilepsy who will only respond to valproate,” he added. “Because it is not possible to predict which women are in this category, neurologists should treat them with another AED before trying valproate,” said Dr. Meador.

To hear an audiocast related to this news article, please click here.